Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03184584 |
Recruitment Status :
Terminated
(Terminated early due to redeployment of study site staff during Covid-19 pandemic)
First Posted : June 12, 2017
Last Update Posted : November 3, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alström Syndrome | Drug: PBI-4050 | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome |
Actual Study Start Date : | October 9, 2017 |
Actual Primary Completion Date : | May 8, 2020 |
Actual Study Completion Date : | May 8, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: PBI-4050 |
Drug: PBI-4050
Four 200 mg capsules (800 mg total) administered orally, once daily |
- Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment [ Time Frame: 96 weeks ]
- Change from baseline in fasting plasma glucose over time [ Time Frame: 96 weeks ]
- Change from baseline in plasma insulin over time [ Time Frame: 96 weeks ]
- Change from baseline in glycated hemoglobin (HbA1c) over time [ Time Frame: 96 weeks ]
- Change from baseline in blood glucose as measured by weekly 4 point profile [ Time Frame: 96 weeks ]
- Change from baseline in the liver stiffness [ Time Frame: 96 weeks ]Measured in kilopascal (kPa) correlated to fibrosis by using a FibroScan

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject completed a preceding ProMetic-sponsored Alström syndrome study with PBI-4050.
- Subject has signed informed consent
- Subject has a documented diagnosis of Alström syndrome
- Subject receiving antidiabetic medications is able and willing to self-monitor blood glucose levels
- Subject must be willing to forego other forms of experimental drug treatment during the study.
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening and agree to use adequate birth control from screening throughout the study and for 30 days after the last Investigational Medicinal Product (IMP) administration
- If a male subject has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for 30 days after the last IMP administration.
Exclusion Criteria:
- Subject discontinued PBI-4050 for safety reasons from any preceding ProMetic-sponsored Alström syndrome study with PBI-4050
- Subject has had a documented episode of severe hypoglycaemia within 12 months before screening and investigator judges that the subject is unable to adequately monitor their glucose levels.
- Subject has uncontrolled hypertension with BP > 170/100 mmHg as determined at screening.
- Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study as determined at screening
- Subject has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance
- Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03184584
United Kingdom | |
University Hospitals Birmingham NHS Foundation Trus | |
Birmingham, United Kingdom, B15 2PR |
Responsible Party: | Liminal BioSciences Ltd. |
ClinicalTrials.gov Identifier: | NCT03184584 |
Other Study ID Numbers: |
PBI-4050-CT-9-10 |
First Posted: | June 12, 2017 Key Record Dates |
Last Update Posted: | November 3, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alstrom Syndrome Syndrome Disease Pathologic Processes Hereditary Sensory and Motor Neuropathy Nervous System Malformations Nervous System Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Polyneuropathies |
Peripheral Nervous System Diseases Neuromuscular Diseases Retinitis Pigmentosa Eye Diseases, Hereditary Eye Diseases Ciliopathies Abnormalities, Multiple Congenital Abnormalities Genetic Diseases, Inborn |